Wolfgang Klietmann
Wolfgang Klietmann is a clinical pathologist and medical microbiologist and serves at Harvard Medical School[1][2][3] faculty as an appointed Lecturer on Pathology. He is considered a leading expert in the areas of infectious diseases and biodefense.
Previously, Klietmann held a staff position as Director of Reference Laboratories in the Department of Pathology at the Massachusetts General Hospital.
Prior to his immigration to the United States in 1992, Klietmann founded and was President/Physician-in-Chief of the Institute of Laboratory Medicine in Düsseldorf Germany[4][4][5][6][7][8][9][10][11][12][13][14][15] a highly recognized institution in terms of the number and quality of scientific publications it generated, and held significant scientific standing for innovative diagnostics among private laboratories in Germany. The company was bought out in the early 1990s by Bioscientia, a subsidiary of Boehringer-Ingelheim.
Klietmann received executive business education in the Owner-President Management Program (OPM12) at Harvard Business School.[16][17] He received his medical education at the University of Freiburg (Germany),[18][19][20][21] and at the Sorbonne and the University of Paris Medical School (France). He performed postdoctoral research work at The Wistar Institute[22][23][24][25][26] at the University of Pennsylvania. For five years, Klietmann headed a research group at the Max-Planck-Institute for Virus Research in Tübingen (Germany),[27][28][29] and served on the medical faculty of the University of Tübingen (Habilitation for Medical Microbiology and Virology 1975), until receiving his academic appointment at Harvard Medical School.[2][3][30]
A prolific author and guest lecturer with over 200 publications and presentations delivered to audiences across the globe, the cornerstone of Klietmann’s career has centered on infectious diseases, including significant contributions in major indicications including rabies, smallpox, AIDS, and tuberculosis.[31][32][33] His work in rabies includes multiple studies investigating efficacy and side effects of tissue culture derived rabies vaccines, as well as leading clinical trials as primary investigator in collaboration with the WHO.[5][11][27][28][29] and served on the medical faculty of the University of Tübingen until receiving his academic appointment at Harvard Medical School.[2][3]
A leading authority on biological warfare and Biodefense, his work includes a collaboration with MIT in a project for the Department of Defense distributed by the CDC to all diagnostic laboratories nationwide for preparedness for weaponized biological attacks.[2] He served as president[34] on the Board of Directors of the Harvard Business School Health Industry Alumni Association and organized as co-chairman several major conferences held on the campus of Harvard Business School and in Washington DC.[35][36]
His memberships in several scientific societies include a Fellowship at the College of American Pathologists. Klietmann is a member of the Board of the Swiss-American Chamber of Commerce New England Chapter.[37]
References[edit]
- ↑ Fischer, Virginia A. (15 November 2005). "Janitors Rally Before Contracts Expire". Harvard Crimson. Retrieved 21 April 2011.
- ↑ 2.0 2.1 2.2 2.3 Klietmann, W. F.; Ruoff, K. L. (2001). "Bioterrorism: Implications for the Clinical Microbiologist". Clinical Microbiology Reviews. 14 (2): 364–81. doi:10.1128/CMR.14.2.364-381.2001. PMC 88979. PMID 11292643.
- ↑ 3.0 3.1 3.2 Wilbur, D. C.; Madi, K; Colvin, R. B.; Duncan, L. M.; Faquin, W. C.; Ferry, J. A.; Frosch, M. P.; Houser, S. L.; Kradin, R. L.; Lauwers, G. Y.; Louis, D. N.; Mark, E. J.; Mino-Kenudson, M; Misdraji, J; Nielsen, G. P.; Pitman, M. B.; Rosenberg, A. E.; Smith, R. N.; Sohani, A. R.; Stone, J. R.; Tambouret, R. H.; Wu, C. L.; Young, R. H.; Zembowicz, A; Klietmann, W (Dec 2009). "Whole-slide imaging digital pathology as a platform for teleconsultation: a pilot study using paired subspecialist correlations". Arch Pathol Lab Med. 133 (12): 1949–53. doi:10.1043/1543-2165-133.12.1949 (inactive 2018-10-20). PMC 3694269. PMID 19961250.
- ↑ 4.0 4.1 Focht, Josef; Klietmanna, Wolfgang; Heilmann, Hans-Dietrich (April 1984). "In vitro-aktivität von augmentin gegen klinisch wichtige gram-positive und gram-negative bakterien im vergleich zu anderen antibiotika" [In-vitro activity of augmentin against clinically important gram-positive and gram-negative bacteria in comparison with other antibiotics]. Zentralblatt für Bakteriologie, Mikrobiologie und Hygiene. 1. Abt. Originale. A, Medizinische Mikrobiologie, Infektionskrankheiten und Parasitologie (in German). 256 (4): 523–30. doi:10.1016/S0174-3031(84)80029-3. PMID 6564828.CS1 maint: Unrecognized language (link)
- ↑ 5.0 5.1 Klietmann, W.; Klietmann, B.; Cox, J.; Charbonnier, C. (1988). "Effectiveness and tolerance of preand postexposure treatment with purified inactivated rabies vaccine prepared on Vero cell line". Vaccine. 6 (1): 39–43. doi:10.1016/0264-410X(88)90012-6. PMID 3354256.
- ↑ Bauernfeind, A.; Grimm, H.; Klietmann, W.; Opferkuch, W.; Werner, H. (1996). "The influence of sulbactam on the in vitro activity of mezlocillin, piperacillin and cefotaxime". International Journal of Antimicrobial Agents. 6: S15–26. doi:10.1016/S0924-8579(96)80003-3. PMID 18611715.
- ↑ Klietmann, W; Cesana, M; Rondel, R K; Focht, J (1993). "Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitis". Antimicrobial Agents and Chemotherapy. 37 (11): 2298–306. doi:10.1128/AAC.37.11.2298. PMC 192382. PMID 8285609.
- ↑ Klietmann, W; Focht, J; Nösner, K (1987). "Comparative in vitro study of the antibacterial effect of cefotetan against gram-positive and gram-negative aerobic and anaerobic strains from fresh clinical isolates". Chemioterapia. 6 (2 Suppl): 92–3. PMID 3509542.
- ↑ Focht, J; Klietmann, W; Nösner, K; Rolinson, GN; Johnsen, J (1988). "Sensitivity of clinical isolates from German hospitals to amoxicillin/clavulanic acid (Augmentin) compared with other antibiotics". Chemotherapy. 34 (4): 332–40. doi:10.1159/000238588. PMID 3264780.
- ↑ Focht, J; Klietmann, W; Nösner, K (1988). "In vitro activity of the combination trimethoprim plus sulfamethoxazole compared with that of other chemotherapeutic agents". Arzneimittel-Forschung. 38 (8): 1085–8. PMID 3264166.
- ↑ 11.0 11.1 Klietmann, W; Klietmann, B; Cox, J; Charbonnier, C (1988). "Effectiveness and tolerance of pre- and postexposure treatment with purified inactivated rabies vaccine prepared on Vero cell line". Vaccine. 6 (1): 39–43. doi:10.1016/0264-410X(88)90012-6. PMID 3354256.
- ↑ Klietmann, W; Focht, J; Nösner, K (1987). "Comparative in vitro study of the antimicrobial activity of ceftazidime against clinical isolates". Infection. 15 Suppl 4: S145–9. doi:10.1007/BF01645861. PMID 3312026.
- ↑ Klietmann, W; Focht, J; Nösner, K (1987). "Comparative in vitro activity of ciprofloxacin against aerobic and anaerobic bacteria from clinical isolates". Arzneimittel-Forschung. 37 (6): 661–6. PMID 2822054.
- ↑ Klietmann, W; Focht, J; Nösner, K (1987). "Antibacterial effect of imipenem in vitro against important aerobic and anaerobic strains isolated from clinical specimens". Chemioterapia. 6 (4): 243–50. PMID 3477332.
- ↑ Focht, J; Heilmann, HD; Heinrich, S; Klietmann, W (1985). "A survey of temocillin sensitivity of strains resistant to newer beta-lactam antibiotics". Drugs. 29 Suppl 5: 78–84. doi:10.2165/00003495-198500295-00016. PMID 3849427.
- ↑ "Wyss Celebrated for Career, Conservation". HBS Alumni Bulletin. March 2011.
- ↑ "Agenda". HBS Health Industry Conference. 2007. Archived from the original on 12 April 2013.
- ↑ Rohr, HP; Klietmann, W; Oehlert, W (1965). "Possibilities of the use of electron microscopic autoradiography". Zeitschrift für die Gesamte Experimentelle Medizin Einschliesslich Experimentelle Chirurgie. 139 (4): 344–56. PMID 5827759.
- ↑ Burmeister, P; Bianchi, L; Klietmann, W; Torhorst, J (1968). "Paraneoplastic Cushing's syndrome in primary liver carcinoma". Deutsche Medizinische Wochenschrift. 93 (4): 164–5. doi:10.1055/s-0028-1105032. PMID 4295844.
- ↑ Oehlert, W; Klietmann, W (1967). "The inhibition of ribonucleic acid synthesis with actinomycin and its recovery in different cell types of the mouse". Beitrage zur Pathologischen Anatomie und zur Allgemeinen Pathologie. 136 (1): 18–33. PMID 4189896.
- ↑ Klietmann, W; Seemayer, N (1971). "Differences in the manifestation of virus-specific surface antigen between cells transformed by SV40 and UV-irradiated SV40". International Journal of Cancer. 7 (1): 50–8. doi:10.1002/ijc.2910070106. PMID 4322938.
- ↑ Sato, N; Chance, B; Kato, K; Klietmann, W (1973). "Comparative study of cytochromes between virus-transformed and untransformed cells". Biochimica et Biophysica Acta. 305 (3): 493–502. doi:10.1016/0005-2728(73)90071-6. PMID 4354788.
- ↑ Sato, Nobuhiro; Chance, Britton; Kato, Kenzo; Klietmann, Wolfgang (1973). "Comparative study of cytochromes between virus-transformed and untransformed cells". Biochimica et Biophysica Acta. 305 (3): 493–502. doi:10.1016/0005-2728(73)90071-6. PMID 4354788.
- ↑ Klietmann, W.; Sato, N; Nass, MM (1973). "ESTABLISHMENT AND CHARACTERIZATION OF ETHIDIUM BROMIDE RESISTANCE IN SIMIAN VIRUS 40-TRANSFORMED HAMSTER CELLS: Effects on Mitochondria in Vivo". The Journal of Cell Biology. 58 (1): 11–26. doi:10.1083/jcb.58.1.11. PMC 2109030. PMID 4353638.
- ↑ Klietmann, W; Kato, K; Gabara, B; Koprowski, H; Sato, N (1973). "Stable alterations in HeLa cell mitochondria following ethidium bromide treatment". Experimental Cell Research. 78 (1): 47–58. doi:10.1016/0014-4827(73)90036-0. PMID 4347915.
- ↑ Klietmann, W; Sato, N; Nass, MM (1973). "Establishment and characterization of ethidium bromide resistance in simian virus 40-transformed hamster cells. Effects on mitochondria in vivo". The Journal of Cell Biology. 58 (1): 11–26. doi:10.1083/jcb.58.1.11. PMC 2109030. PMID 4353638.
- ↑ 27.0 27.1 Wolf, G; Tejmar, L; Borell, S; Klietman, W (1978). "SV40-transformed hamster cells resistant to 100--250 microgram/ml of ethidium bromide". Journal of Cell Science. 33: 157–69. PMID 214453.
- ↑ 28.0 28.1 Cox, JH; Klietmann, W; Schneider, LG (1978). "Human rabies immunoprophylaxis using HDC (MRC-5) vaccine". Developments in Biological Standardization. 40: 105–8. PMID 680382.
- ↑ 29.0 29.1 Klietmann, W; Domres, B; Cox, JH (1978). "Rabies post-exposure treatment and side-effects in man using HDC (MRC 5) vaccine". Developments in Biological Standardization. 40: 109–13. PMID 567152.
- ↑ Klietmann, Wolfgang (Sep 1, 2005). "Thought Leader: (Eco)systemic Change". Pharmaceutical Executive.
- ↑ Stelzner, A. (1990). "W. KLIETMANN (Herausgeber), AIDS – Forschung, Klinik, Praxis, soziokulturelle Aspekte (2., überarbeitete und wesentlich erweiterte Auflage). XVI + 240 S., 88 Abb., 26 Tab. Stuttgart – New York 1990. F. K. Schattauer Verlagsgesellschaft mbH. DM 59,00". Journal of Basic Microbiology. 30 (9): 684. doi:10.1002/jobm.3620300915. ISBN 3-7945-1234-0.
- ↑ http://webweekly.hms.harvard.edu/archive/2004/2_2/upcoming.html[full citation needed]
- ↑ http://www.hofstra.edu/pdf/community/culctr/culctr_program_icasm.pdf[full citation needed]
- ↑ http://www.hbshealthalumni.org/board.html[full citation needed]
- ↑ "Wolfgang Klietmann - HBS Health Industry Alumni Association".
- ↑ http://ypohealthcare.com/pdf/http___www.ypohealthcare.com_meeting_info-dc.pdf[full citation needed]
- ↑ http://www.amcham.ch/chapters/downloads/20100304_BO_swiss_healthcare.pdf[full citation needed]
This article "Wolfgang Klietmann" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Wolfgang Klietmann. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
